Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study

DehydraTECH^TM-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus:

• Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours;
• Lower blood-glucose spike after eating; and
• Successful first-ever DehydraTECH test with a "large molecule" drug.

KELOWNA, BC / ACCESSWIRE / November 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces additional positive interim results from a human pilot study (the "Study") evaluating DehydraTECH^TM technology for the oral delivery of the glucagon-like peptide-1 ("GLP-1") drug semaglutide available commercially in the branded product Rybelsus, further to its previously announced findings from this work.

The Study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet ("Control") to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements ("DehydraTECH GLP-1").

Blood Glucose Levels
It is accepted by the Food and Drug Administration ("FDA") that, "one role of GLP-1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar)." Because blood glucose levels are a key consideration in control of diabetes and other health conditions, the Study measured blood glucose levels at each of the 19 sample time points.

Blood Glucose Levels

Foto: Accesswire

Rybelsus (blue) 7mg (n=3) DehydraTECH (orange) GLP-1 7mg (n=4)

The Control group evidenced reduced blood glucose levels by between 1.3% and 6.7% relative to the time zero baseline during the first 100 minutes of the Study. The DehydraTECH GLP-1 group evidenced reduced blood glucose levels by between 2.9% and 14.6% relative to baseline during those same initial 100 minutes. At all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the Control group.

Notably, even as long as 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline while the blood glucose level evidenced in the Control group was only reduced by 0.67%, evidencing nearly a ten-fold improvement with the DehydraTECH GLP-1. (Only the first 10 hours of study results displayed in the graph above.)